FOLFIRINOX in Patients With Inoperable Pancreatic Cancer
Status:
Terminated
Trial end date:
2013-10-01
Target enrollment:
Participant gender:
Summary
The prognosis of patients with locally advanced unresectable pancreatic cancer is poor, and
the median survival is less than 1 year. FOLFIRINOX therapy, which induces tumor downstaging
sufficient to allow surgical resection, could improve the overall survival of patients with
locally advanced pancreatic cancer. Based on the FOLFIRINOX regimen for advanced pancreatic
cancer, a phase II study of this regimen in patients with locally advanced unresectable and
borderline pancreatic cancer is planned to determine the rate of conversion to operability.